Vijaya Diagnostics Centre limited is a leading diagnostic medicare services provider in Southern India and offers comprehensive services that include nuclear medicine, radiology, laboratory, health check-ups and medical services. The company provides its services across 13 cities through its 81 diagnostic centers and 11 reference laboratories.[1]
Market LeadershipThe company is the largest integrated diagnostic chain in South India.[1]It was among the first in South India to offer PET-CT scans.[2]
| S.No. | Name | Current Price (Rs.) | Price to Earning | Market Capitalization (Rs.Cr.) | Dividend yield (%) | Net Profit latest quarter (Rs.Cr.) | YOY Quarterly profit growth (%) | Sales latest quarter (Rs.Cr.) | YOY Quarterly sales growth (%) | Return on capital employed (%) | Sales (Rs.Cr.) | OPM (%) | Profit after tax (Rs.Cr.) | Profit after tax latest quarter (Rs.Cr.) | Price to book value | Return on assets (%) | Debt to equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Dr Lal Pathlabs | 1479.30 | 46.39 | 24785.82 | 0.81 | 152.20 | 16.41 | 730.60 | 10.66 | 28.88 | 2599.70 | 28.44 | 534.30 | 150.40 | 10.38 | 19.11 | 0.07 |
| 2. | Vijaya Diagnost. | 1048.70 | 72.37 | 10772.76 | 0.19 | 42.70 | 7.42 | 189.35 | 11.07 | 20.20 | 682.19 | 40.34 | 148.86 | 42.70 | 12.74 | 11.91 | 0.40 |
| 3. | Metropolis Healt | 2029.80 | 66.48 | 10518.83 | 0.20 | 52.89 | 13.22 | 429.19 | 22.70 | 14.66 | 1483.31 | 22.40 | 158.23 | 52.67 | 7.34 | 8.24 | 0.14 |
| 4. | Thyrocare Tech. | 468.45 | 58.37 | 7455.93 | 1.49 | 47.81 | 79.94 | 216.53 | 22.09 | 24.78 | 762.64 | 29.86 | 127.73 | 47.99 | 13.94 | 12.86 | 0.05 |
| 5. | Nephrocare Health Services | 492.55 | 74.30 | 4942.28 | 0.00 | 14.23 | – | 473.50 | – | 14.11 | 755.81 | 22.05 | 66.52 | 14.23 | – | 7.39 | 0.36 |
| 6. | Krsnaa Diagnost. | 752.10 | 28.54 | 2439.71 | 0.37 | 23.24 | 5.78 | 182.88 | 2.33 | 12.52 | 698.31 | 29.97 | 85.47 | 23.24 | 2.62 | 6.46 | 0.30 |
| 7. | Suraksha Diagno. | 270.80 | 44.17 | 1410.35 | 0.00 | 8.83 | -13.06 | 78.73 | 17.95 | 17.84 | 275.92 | 30.91 | 31.93 | 8.99 | 6.12 | 9.83 | 0.51 |
| – | Median: 13 Co. | 492.55 | 36.36 | 1410.35 | 0.0 | 18.15 | 13.22 | 186.12 | 16.3 | 24.78 | 682.19 | 29.86 | 49.1 | 17.7 | 6.12 | 12.86 | 0.14 |
Standalone figures in ₹ crores
| Dec 2022 | Dec 2023 | Dec 2024 | Jun 2023 | Jun 2024 | Jun 2025 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 111 | 129 | 156 | 119 | 142 | 177 | 118 | 141 | 160 | 118 | 136 | 170 | 189 |
Expenses | 67 | 78 | 94 | 71 | 87 | 107 | 70 | 84 | 96 | 70 | 80 | 100 | 111 |
Operating Profit | 44 | 51 | 62 | 47 | 56 | 70 | 48 | 57 | 64 | 48 | 56 | 71 | 79 |
Other Income | 4 | 3 | 5 | 6 | 4 | 7 | 5 | 3 | 5 | 3 | 7 | 5 | 5 |
Profit before tax | 22 | 34 | 44 | 35 | 38 | 52 | 36 | 40 | 45 | 31 | 44 | 54 | 57 |
Tax % | 25% | 25% | 24% | 26% | 25% | 26% | 24% | 23% | 27% | 25% | 25% | 26% | 25% |
Net Profit | 16 | 25 | 34 | 26 | 29 | 39 | 27 | 31 | 33 | 23 | 33 | 40 | 43 |
EPS in Rs | 1.58 | 2.47 | 3.27 | 2.55 | 2.81 | 3.77 | 2.64 | 2.98 | 3.23 | 2.25 | 3.21 | 3.87 | 4.16 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
Sales | 238 | 279 | 329 | 367 | 451 | 450 | 525 | 627 | 682 |
Expenses | 160 | 187 | 196 | 204 | 251 | 271 | 313 | 374 | 407 |
Operating Profit | 78 | 92 | 133 | 163 | 200 | 179 | 212 | 253 | 275 |
Other Income | 5 | 9 | 12 | 11 | 13 | 15 | 19 | 18 | 22 |
Interest | 4 | 4 | 15 | 15 | 16 | 21 | 24 | 25 | 27 |
Depreciation | 23 | 26 | 48 | 50 | 52 | 61 | 55 | 65 | 72 |
Profit before tax | 56 | 70 | 82 | 110 | 144 | 111 | 152 | 181 | 199 |
Net Profit | 35 | 49 | 61 | 83 | 108 | 83 | 115 | 135 | 148 |
EPS in Rs | 78.17 | 108.02 | 135.13 | 18.28 | 10.60 | 8.15 | 11.20 | 13.15 | 14.43 |
Dividend Payout % | 0% | 0% | 0% | 0% | 9% | 12% | 9% | 15% | – |
Standalone figures in ₹ crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5 | 5 | 5 | 5 | 10 | 10 | 10 | 10 | 10 |
Reserves | 162 | 211 | 273 | 356 | 460 | 535 | 643 | 773 | 835 |
Borrowings | 26 | 36 | 156 | 137 | 183 | 248 | 250 | 292 | 338 |
Other Liabilities | 31 | 40 | 41 | 36 | 58 | 57 | 59 | 148 | 154 |
Total Liabilities | 224 | 292 | 475 | 533 | 711 | 850 | 962 | 1,224 | 1,337 |
Fixed Assets | 102 | 137 | 264 | 261 | 364 | 517 | 582 | 672 | 773 |
Gross Block | 145.34 | 204.27 | 377.96 | 422.25 | 574.78 | 785.40 | 899.62 | 1,050.99 | – |
Accumulated Depreciation | 43.46 | 67.69 | 114.04 | 161.68 | 211.06 | 268.29 | 317.19 | 379.20 | – |
CWIP | 3 | 3 | 10 | 9 | 34 | 28 | 9 | 67 | 45 |
Investments | 77 | 73 | 58 | 32 | 59 | 144 | 254 | 328 | 370 |
Other Assets | 42 | 80 | 143 | 231 | 254 | 161 | 117 | 157 | 149 |
Total Assets | 224 | 292 | 475 | 533 | 711 | 850 | 962 | 1,224 | 1,337 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
Cash from Operating Activity | 62 | 77 | 109 | 128 | 155 | 163 | 175 | 207 |
Cash from Investing Activity | -100 | -91 | -34 | -129 | -127 | -108 | -139 | -165 |
Cash from Financing Activity | -7 | 8 | -28 | -48 | -25 | -41 | -43 | -47 |
Net Cash Flow | -44 | -7 | 46 | -49 | 4 | 13 | -8 | -6 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
Debtor Days | 14 | 14 | 9 | 7 | 8 | 7 | 9 | 7 |
Inventory Days | 24 | 19 | 23 | 16 | 22 | 12 | 26 | 17 |
Days Payable | 152 | 175 | 163 | 133 | 108 | 172 | 178 | 141 |
Cash Conversion Cycle | -115 | -142 | -130 | -110 | -79 | -153 | -143 | -116 |
Working Capital Days | -22 | -28 | -40 | -21 | -32 | -37 | -28 | -48 |
ROCE % | – | 33% | 27% | 27% | 28% | 18% | 19% | 20% |
Direct from BSE filings, auto-summarised
External media mentions & references
Editorial & research coverage
Nov 2025
Aug 2025
May 2025
Feb 2025
Nov 2024
Aug 2024
Jun 2024
May 2024
Feb 2024
Dec 2023
Nov 2023
Aug 2023
Jun 2023
Feb 2023
Nov 2022
Aug 2022
Jun 2022
Feb 2022
Nov 2021
Stock Analysis
Vijaya Diagnostic Centre Limited is a leading integrated diagnostic service provider in South India, offering a comprehensive suite of services including nuclear medicine, radiology, and laboratory diagnostics through an extensive network of centers.
The successful allotment of shares post-amalgamation with Medinova Diagnostic Services Limited marks the completion of a significant corporate restructuring, aiming to create operational synergies and expand market reach.
Currently no data available for Order Book.
Currently no data available for Key Red Flags.
The NCLT order approving the amalgamation was dated October 13, 2025, the amalgamation became effective on November 04, 2025, and the record date for share allotment was November 25, 2025.
Corporate Announcements
